Mersana Therapeutics, Inc. (MRSN)
| Previous close | 3.5200 |
| Open | 3.4400 |
| Bid | 3.4600 x 100 |
| Ask | 3.5000 x 600 |
| Day's range | 3.3800 - 3.5584 |
| 52-week range | 0.8010 - 9.6200 |
| Volume | |
| Avg. volume | 2,157,835 |
| Market cap | 419.708M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.71 |
ZacksStrength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
GlobeNewswireMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common s
Insider MonkeyMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all […]
